



## **Verastem to Present at Rodman & Renshaw 18th Annual Global Investment Conference**

September 6, 2016

BOSTON--(BUSINESS WIRE)--Sep. 6, 2016-- Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer, today announced that the company will present at the Rodman & Renshaw 18th Annual Global Investment Conference on Tuesday, September 13th at 10:25 AM Eastern Time at The Lotte New York Palace Hotel.

A live audio webcast of the presentation will be available on the company's website at [www.verastem.com](http://www.verastem.com). An archived presentation will be available for 90 days.

### **About Verastem, Inc.**

Verastem, Inc. (NASDAQ:VSTM) is a biopharmaceutical company focused on discovering and developing drugs to improve outcomes for patients with cancer. Our product candidates utilize a multi-faceted approach to treat cancer by reducing cancer stem cells, enhancing anti-tumor immunity, and modulating the local tumor microenvironment. Our most advanced clinical product candidates are the Focal Adhesion Kinase inhibitors, VS-6063 and VS-4718, and the dual PI3K/mTOR inhibitor, VS-5584. For more information, please visit [www.verastem.com](http://www.verastem.com).

View source version on businesswire.com: <http://www.businesswire.com/news/home/20160906005306/en/>

Source: Verastem, Inc.

### **Verastem, Inc.**

Brian Sullivan, 781-292-4214

[bsullivan@verastem.com](mailto:bsullivan@verastem.com)